Authored by Cyan Health, now part of Lumanity

As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma to be more active in sharing HEOR information, and I think that helps.”

That regulatory development—and the payer’s sentiment—point the way to important communication opportunities for pharma brands. It is now incumbent upon market access teams to make the most of those opportunities.

Read the full piece at PM360